Our investigational drug product candidate, DM199 is a synthetic form of the human tissue kallikrein-1 protein (KLK1), which is primarily produced in the kidneys, as well as in the pancreas and salivary glands. We believe that DM199 has the potential to treat several diseases where sufficient levels of KLK1 are necessary for healthy function.
ReMEDy2 is a Phase 2/3 study investigating DM199 (rhKLK1) as a novel acute ischemic stroke (AIS) treatment intended to safely improve stroke recoveries in a patient population with no treatment options.
DM199 for Pregnancy Complications is a Phase 2 trial assessing DM199 (rhKLK1) as a potential therapy for preeclampsia and fetal growth restriction – conditions with no FDA-approved therapies.
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and effectiveness of DM199 for the treatment of acute ischemic stroke or preeclampsia has not been established and is limited to investigational use only.
